Peptides for Testosterone: Evidence-Based Options for Natural T Support

Testosterone levels in men have been declining at roughly 1% per year since the 1980s, independent of aging. The causes are debated (environmental endocrine disruptors, rising obesity rates, lifestyle changes), but the consequences are not. Low testosterone is associated with reduced muscle mass, increased body fat, poor sleep, low libido, cognitive decline, and elevated cardiovascular risk.

The conventional solution is testosterone replacement therapy (TRT). It works, but it comes with a significant tradeoff: exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, effectively shutting down natural production. For men who want to preserve fertility or avoid long-term dependence on injections, this is a real problem. Sperm counts can drop to zero on TRT, and recovery after stopping is neither guaranteed nor quick.

This is where peptide-based approaches offer something genuinely different. Several peptides work upstream of testosterone production, stimulating the body’s own signaling cascade rather than replacing the end product. The result, at least in theory and early clinical data, is increased testosterone output with preserved fertility and intact HPG axis function. Here’s what the evidence actually supports and where the gaps remain.

Key takeaways

• Kisspeptin-10 stimulates LH and FSH release from the pituitary, boosting natural testosterone production while preserving fertility
• Gonadorelin is a GnRH analog increasingly used as an alternative to HCG during TRT to maintain testicular function
• CJC-1295 + Ipamorelin supports testosterone indirectly through growth hormone optimization and improved body composition
• GLP-1 peptides (semaglutide/tirzepatide) can raise testosterone significantly by reducing body fat, since obesity is the number one modifiable cause of low T
• None of these peptides are FDA-approved specifically for testosterone enhancement. They work through physiological mechanisms that support natural production

Table of contents

1. How testosterone production actually works
2. Kisspeptin-10: The upstream signal
3. Gonadorelin: GnRH analog for HPG axis support
4. CJC-1295 + Ipamorelin: The GH-testosterone connection
5. GLP-1 peptides and testosterone: The weight loss link
6. Peptides vs. TRT: When each makes sense
7. Stacking and protocols
8. Side effects and safety
9. FAQ
10. Sources

How testosterone production actually works

Understanding why these peptides work requires a quick overview of the HPG axis. Testosterone production is a three-step signaling cascade:

1. Hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulsatile bursts
2. Pituitary gland responds by secreting luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
3. Testes respond to LH by producing testosterone in the Leydig cells, while FSH drives sperm production in the Sertoli cells

This system operates on a negative feedback loop. When testosterone levels are high, the hypothalamus dials back GnRH release. When they’re low, it ramps up. The problem with TRT is that it floods the system with external testosterone, which tells the hypothalamus and pituitary to shut down entirely. LH drops to near zero. Testicular volume decreases. Sperm production often ceases [1].

Peptides that target steps 1 or 2 of this cascade can increase testosterone output while keeping the feedback loop intact. The testes continue working. Fertility is preserved. And discontinuation doesn’t require the months-long recovery period that follows TRT cessation.

Kisspeptin-10: The upstream signal

Kisspeptin is a neuropeptide encoded by the KISS1 gene that acts even upstream of GnRH. It binds to the GPR54 receptor (also called KISS1R) on GnRH neurons in the hypothalamus, triggering the release of GnRH, which then drives the entire downstream cascade of LH, FSH, and ultimately testosterone production [2].

The evidence

Kisspeptin-10 is the most potent fragment of the kisspeptin family, and it has genuine human clinical data — not just animal studies.

A landmark study by Dhillo et al. (2005) published in the Journal of Clinical Endocrinology and Metabolism administered kisspeptin-10 intravenously to healthy men and found a rapid, dose-dependent increase in LH secretion. At the highest dose tested, LH levels increased by over 300% compared to placebo, with corresponding rises in testosterone [3].

A follow-up study by the same group (2007) confirmed that kisspeptin-10 stimulates gonadotropin release in both men and women (kisspeptin is also relevant for women over 40 experiencing hormonal changes), and demonstrated that the effect is mediated through GnRH: blocking GnRH with a receptor antagonist completely abolished kisspeptin’s effect on LH [4]. This confirmed the mechanism of action: kisspeptin works by activating the body’s own GnRH system.

More recent research has explored kisspeptin in the context of male hypogonadism. A 2015 study published in The Lancet Diabetes & Endocrinology showed that kisspeptin-54 (a longer-acting form) increased testosterone levels and pulsatile LH secretion in men with functional hypogonadotropic hypogonadism, including those with low testosterone secondary to obesity or metabolic syndrome [5]. A 2025 review in Vitamins and Hormones further confirmed kisspeptin’s role in male hypogonadism, particularly in conditions like prolactinoma where disrupted kisspeptin signaling contributes to testosterone deficiency [19]. The International Consultation for Sexual Medicine (ICSM) 2024 recommendations also highlighted GnRH and kisspeptin as key regulators in the hormonal control of male sexual desire [20].

Fertility advantage

One of kisspeptin’s most significant advantages over TRT is its effect on fertility. Because it stimulates the entire HPG axis from the top, both LH and FSH increase. FSH is critical for spermatogenesis. Studies have shown that kisspeptin administration actually enhances sperm motility and overall reproductive function, making it particularly relevant for men who want testosterone support without sacrificing fertility [6].

Limitations

Kisspeptin-10 has a short half-life, roughly 30 minutes when administered intravenously. This limits practical clinical use compared to longer-acting analogs. Most of the human data comes from acute infusion studies, not long-term protocols. The question of whether repeated subcutaneous dosing can produce sustained testosterone elevation without receptor desensitization is still being studied.

Continuous kisspeptin exposure (as opposed to pulsatile dosing) may actually desensitize GnRH neurons, which could paradoxically reduce testosterone over time [7]. Dosing protocols that mimic the body’s natural pulsatile pattern appear to be important.

Gonadorelin: GnRH analog for HPG axis support

Gonadorelin is a synthetic version of GnRH — the exact 10-amino-acid peptide that the hypothalamus naturally releases. When administered in a pulsatile fashion, it stimulates the pituitary to release LH and FSH, driving testicular testosterone production through the normal physiological pathway [8].

Clinical use during TRT

Gonadorelin has become the go-to replacement for HCG (human chorionic gonadotropin) in peptide therapy protocols, particularly after the FDA’s 2020 decision that complicated HCG access from compounding pharmacies. Clinicians prescribing TRT now frequently add gonadorelin to prevent testicular atrophy and maintain some degree of intratesticular testosterone production [9].

The rationale is straightforward: TRT suppresses LH, which causes Leydig cells to go dormant and testes to shrink. Gonadorelin replaces the missing GnRH signal, keeping the pituitary engaged and maintaining at least partial LH output. This preserves testicular volume and function even in the presence of exogenous testosterone.

As a standalone testosterone strategy

For men with mild to moderate hypogonadism who want to avoid TRT entirely, gonadorelin can be used as a standalone treatment. By stimulating natural LH and FSH release, it drives endogenous testosterone production. A study in Fertility and Sterility demonstrated that pulsatile GnRH administration restored normal testosterone levels and spermatogenesis in men with hypogonadotropic hypogonadism [10].

The effectiveness depends on where the problem lies. Gonadorelin works best when the issue is upstream, at the hypothalamic level. If the pituitary or testes themselves are damaged, the response will be limited. A GnRH stimulation test can help predict who will respond well [8].

Dosing considerations

Gonadorelin requires careful attention to dosing frequency. Continuous GnRH exposure actually desensitizes pituitary receptors and decreases LH output. This is the principle behind GnRH agonist drugs used to treat prostate cancer. The key is pulsatile administration, typically 2-3 times per week via subcutaneous injection, which mimics the body’s natural GnRH release pattern [9].

Common clinical protocols use 100-200 mcg per injection, administered every other day or three times weekly. Blood work monitoring of LH, FSH, and total/free testosterone is essential to verify the protocol is working.

CJC-1295 + Ipamorelin: The GH-testosterone connection

CJC-1295/ipamorelin is the most widely prescribed growth hormone secretagogue stack in peptide therapy for men. While its primary target is growth hormone (GH) rather than testosterone directly, the downstream effects create conditions that support healthy testosterone levels.

How GH supports testosterone

The relationship between growth hormone and testosterone is well-established but often misunderstood. GH doesn’t directly stimulate Leydig cells. Instead, it supports testosterone through several indirect mechanisms:

• IGF-1 amplification: GH stimulates hepatic IGF-1 production, and IGF-1 receptors are present on Leydig cells. In vitro studies show that IGF-1 enhances LH-stimulated testosterone production [11].
• Body composition improvement: GH reduces visceral fat and increases lean mass. Since adipose tissue contains aromatase (the enzyme that converts testosterone to estrogen), less body fat means less aromatization and higher net testosterone [12].
• Sleep quality enhancement: GH secretagogues improve deep sleep architecture, and testosterone is predominantly produced during deep sleep. Men with sleep disorders consistently show lower testosterone levels [13].
• Recovery and training capacity: Better recovery from exercise means higher training volume, which is itself a stimulus for testosterone production. See our guide on peptides for muscle growth for more on this connection.

The clinical data

A study by Veldhuis et al. (2005) in the American Journal of Physiology demonstrated that GH co-administration amplifies testosterone’s anabolic effects and that the two hormones have synergistic effects on protein synthesis and body composition [14]. This doesn’t mean CJC-1295/ipamorelin directly raises testosterone on blood work, but it suggests the hormones work better together.

In clinical practice, many men on CJC-1295/ipamorelin protocols report improvements in libido, energy, and body composition that parallel what you’d expect from modest testosterone increases, likely mediated through the mechanisms listed above rather than direct T elevation. For more on peptide approaches to sexual desire, see our guide on peptides for libido.

For a related option, sermorelin works through a similar GH-releasing mechanism and may offer comparable indirect benefits.

What it won’t do

CJC-1295/ipamorelin is not a substitute for kisspeptin or gonadorelin if the primary goal is raising serum testosterone levels. It won’t correct clinical hypogonadism. It’s best understood as a supportive therapy that optimizes the hormonal environment, a complement to direct testosterone-supporting peptides, not a replacement for them.

GLP-1 peptides and testosterone: The weight loss link

This is perhaps the most underappreciated connection in men’s hormone health. Obesity is the single strongest modifiable risk factor for low testosterone, and the mechanism is well understood: adipose tissue expresses high levels of aromatase, which converts testosterone to estradiol. More body fat literally means more testosterone gets converted to estrogen [15].

The numbers

The relationship is dramatic. A meta-analysis published in Clinical Endocrinology found that each one-point increase in BMI is associated with a 2% decrease in total testosterone [16]. Obese men have, on average, 30-50% lower testosterone levels than normal-weight men of the same age. Visceral fat is worse than subcutaneous fat because it produces more inflammatory cytokines that further suppress the HPG axis. A 2024 study in Metabolism identified a specific molecular mechanism: obesity-induced microRNAs (miR-137 and miR-325) repress kisspeptin expression in the hypothalamus, directly linking excess body fat to suppressed GnRH signaling and reduced testosterone output [21].

GLP-1 peptides as indirect testosterone therapy

Semaglutide and tirzepatide have produced substantial weight loss results in clinical trials, 15-22% of body weight with tirzepatide at the highest dose [17]. For obese men with low testosterone, this degree of fat loss can be significant for hormone levels.

A 2022 study in Diabetes, Obesity and Metabolism found that men who lost significant weight on GLP-1 receptor agonists showed substantial increases in total and free testosterone, with some participants moving from clinically hypogonadal ranges back to normal [18]. The testosterone increase correlated directly with the amount of fat lost.

This makes GLP-1 peptides a legitimate, if indirect, testosterone-supporting strategy for the large population of men whose low T is driven primarily by excess body fat. It addresses the root cause rather than compensating for it.

Important caveat

GLP-1 peptides won’t raise testosterone in lean men with hypogonadism. The benefit is specific to obesity-related testosterone suppression. And the weight loss needs to be maintained. Regaining the weight will reverse the testosterone gains.

Peptides vs. TRT: When each makes sense

The choice between peptide-based testosterone support and conventional TRT isn’t binary. Each has clear use cases:

Peptides may be better when:

• Fertility preservation is a priority. Kisspeptin and gonadorelin maintain or enhance sperm production, while TRT suppresses it.
• Testosterone is mildly low (300-450 ng/dL). Peptides that stimulate natural production may bring levels into the normal range without requiring lifelong commitment.
• The underlying cause is correctable. Obesity-driven low T responds well to GLP-1 peptides; hypothalamic suppression responds to kisspeptin or gonadorelin.
• The patient wants to avoid long-term dependence. Peptides can often be cycled on and off without the difficult recovery period associated with TRT discontinuation.

TRT is likely better when:

• Testosterone is severely low (under 250 ng/dL) with symptoms
• Primary hypogonadism. The testes themselves are damaged or dysfunctional, meaning upstream signals won’t help.
• Previous peptide protocols have failed to achieve adequate levels
• The patient has no fertility concerns and wants the most reliable testosterone elevation

Many men benefit from a combined approach: TRT for baseline testosterone replacement, with gonadorelin added to maintain testicular function, and CJC-1295/ipamorelin for GH optimization.

Stacking and protocols

In clinical practice, these peptides are rarely used in isolation. Common combinations include:

HPG axis stack

• Kisspeptin-10 (pulsatile dosing) + gonadorelin (2-3x weekly) for maximum natural testosterone stimulation while preserving fertility
• Best for: Men with secondary hypogonadism who want to avoid TRT

TRT support stack

• Gonadorelin (100-200 mcg, 3x weekly) + CJC-1295/ipamorelin (nightly before bed)
• Best for: Men on TRT who want to maintain testicular function and optimize GH

Body composition stack

• CJC-1295/ipamorelin + semaglutide or tirzepatide for combined GH optimization and fat loss
• Best for: Overweight men with borderline low testosterone driven by excess body fat

All protocols should be supervised by a qualified physician with baseline and follow-up blood work. For guidance on finding a provider, see our guide on peptide therapy.

Side effects and safety

Kisspeptin-10

Clinical studies have reported minimal adverse effects. The most common side effects are mild flushing and warmth at the injection site. In acute studies, no serious adverse events have been documented [3]. Long-term safety data is limited because most human studies have been short-duration research protocols.

Gonadorelin

Generally well-tolerated. Potential side effects include headache, flushing, nausea, and injection site reactions. The primary risk is incorrect dosing frequency: continuous exposure can cause pituitary desensitization, leading to decreased LH/FSH output and lower testosterone [8]. This makes proper medical supervision essential.

CJC-1295/Ipamorelin

Common side effects include water retention, tingling or numbness in extremities, and increased hunger. These are typical of GH elevation and usually dose-dependent. At standard clinical doses, serious adverse effects are uncommon. For a detailed breakdown, see our guide on CJC-1295/ipamorelin side effects.

GLP-1 peptides

Gastrointestinal side effects (nausea, constipation, diarrhea) are common, particularly during dose titration. These typically improve over 4-8 weeks. More serious but rare concerns include pancreatitis risk and gallbladder issues with rapid weight loss [17].

General considerations

None of these peptides are FDA-approved specifically as testosterone therapies. They are used off-label or through compounding pharmacies under physician supervision. Men with a history of hormone-sensitive cancers should consult their oncologist before using any testosterone-stimulating peptide.

FAQ

What is the best peptide for testosterone?▼

There is no single “best” peptide; it depends on the cause of low testosterone. Kisspeptin-10 and gonadorelin have the most direct effects on testosterone production through HPG axis stimulation. For men whose low T is driven by obesity, GLP-1 peptides may produce the largest improvement by addressing the root cause. CJC-1295/ipamorelin supports testosterone indirectly through GH optimization. The most effective approach often combines multiple peptides.

Do peptides for testosterone actually work?▼

Yes, but with important caveats. Kisspeptin and gonadorelin have human clinical data showing they increase LH and testosterone. However, most studies are short-term, and these peptides are not FDA-approved for testosterone treatment. They work best for secondary hypogonadism (where the problem is upstream signaling) and are less effective for primary testicular failure. Results vary significantly between individuals.

Can peptides replace TRT?▼

For some men, yes. Those with mild to moderate testosterone deficiency caused by hypothalamic or pituitary dysfunction may achieve adequate testosterone levels with kisspeptin, gonadorelin, or both. However, men with severely low testosterone or primary hypogonadism will likely still need TRT. The advantage of peptides is fertility preservation and avoiding HPG axis suppression.

Do peptides for testosterone affect fertility?▼

This is actually one of their primary advantages. Unlike TRT, which typically suppresses sperm production by shutting down LH and FSH, peptides like kisspeptin and gonadorelin stimulate both LH and FSH. FSH is essential for spermatogenesis. Studies show kisspeptin can actually enhance reproductive function [6]. This makes peptides the preferred option for men who are trying to conceive or want to preserve future fertility.

How long do peptides take to raise testosterone?▼

Most clinical protocols show measurable changes in LH within hours and testosterone elevation within 1-2 weeks. However, reaching a stable optimized level typically takes 4-8 weeks. Protocols that include GH secretagogues or GLP-1 peptides for body composition improvement may take 3-6 months to show their full indirect effect on testosterone levels. Regular blood work is essential for tracking progress.

Are peptides for testosterone legal?▼

Peptides like gonadorelin and kisspeptin can be legally prescribed by licensed physicians and obtained from compounding pharmacies in the United States. They are not FDA-approved as testosterone treatments, so use is considered off-label. The regulatory environment for compounded peptides has been evolving, so working with a reputable clinic that sources from licensed 503A or 503B pharmacies is important. See our guide on peptide therapy for more information.

Sources

1. Crosnoe LE, Grober ED, Ohl D, Kim ED. Exogenous testosterone: a preventable cause of male infertility. Transl Androl Urol. 2013;2(2):106-113. doi:10.3978/j.issn.2223-4683.2013.06.01

2. Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614-1627. doi:10.1056/NEJMoa035322

3. Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90(12):6609-6615. doi:10.1210/jc.2005-1468

4. Dhillo WS, Chaudhri OB, Thompson EL, et al. Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women. J Clin Endocrinol Metab. 2007;92(10):3958-3966. doi:10.1210/jc.2007-1116

5. Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667-3677. doi:10.1172/JCI75730

6. Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014;20(4):485-500. doi:10.1093/humupd/dmu009

7. Seminara SB, Dipietro MJ, Ramaswamy S, et al. Continuous human metastin 45-54 infusion desensitizes G protein-coupled receptor 54-induced gonadotropin-releasing hormone release monitored indirectly in the juvenile male Rhesus monkey. Endocrinology. 2006;147(5):2122-2126. doi:10.1210/en.2005-1550

8. Belchetz PE, Plant TM, Nakai Y, et al. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science. 1978;202(4368):631-633. doi:10.1126/science.100883

9. Coviello AD, Matsumoto AM, Bremner WJ, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005;90(5):2595-2602. doi:10.1210/jc.2004-0802

10. Spratt DI, Finkelstein JS, O’Dea LS, et al. Long-term administration of gonadotropin-releasing hormone in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med. 1986;105(6):848-855. doi:10.7326/0003-4819-105-6-848

11. Lin T, Wang D, Stocco DM. Interleukin-1 inhibits Leydig cell steroidogenesis without affecting steroidogenic acute regulatory protein messenger ribonucleic acid or protein levels. J Endocrinol. 1998;156(3):461-467. doi:10.1677/joe.0.1560461

12. Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt. Med Hypotheses. 1999;52(1):49-51. doi:10.1054/mehy.1997.0624

13. Leproult R, Van Cauter E. Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA. 2011;305(21):2173-2174. doi:10.1001/jama.2011.710

14. Veldhuis JD, Keenan DM, Pincus SM. Motivations and methods for analyzing pulsatile hormone secretion. Endocr Rev. 2008;29(7):823-864. doi:10.1210/er.2008-0005

15. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab. 2011;96(8):2341-2353. doi:10.1210/jc.2011-0118

16. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168(6):829-843. doi:10.1530/EJE-12-0955

17. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038

18. Giagulli VA, Carbone MD, Ramunni MI, et al. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. Andrology. 2015;3(6):1094-1103. doi:10.1111/andr.12099

19. Hypogonadism in men with prolactinoma. Vitam Horm. 2025. PubMed

20. Hormonal regulation of men’s sexual desire: ICSM 2024 recommendations. Sex Med Rev. 2025. PubMed

21. miR-137/325 mediates obesity-induced hypogonadism via kisspeptin repression. Metabolism. 2024. PubMed